Schwaller Kathryn, Krauss Zachary, Chen Aleda M H, Cole Justin W
Department of Pharmacy Practice, Cedarville University School of Pharmacy, Cedarville, OH.
J Pediatr Pharmacol Ther. 2023;28(4):323-328. doi: 10.5863/1551-6776-28.4.323. Epub 2023 Aug 9.
Data evaluating the use of unlicensed cannabidiol (CBD) products for the treatment of -symptoms associated with anxiety and neurodevelopmental disorders in children are limited despite increasing -product availability. The objectives of this study are to quantify the usage of unlicensed CBD products among pediatric patients diagnosed with anxiety and neurodevelopmental disorders and compare the -perceptions of CBD between parents who administer a CBD product to a child and parents who do not.
A survey containing 31 items was designed after pretesting with pediatric health care professionals. The refined survey was distributed using Qualtrics Panels to a representative sample of US parents of a child 7 to 18 years of age diagnosed with attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and/or generalized anxiety disorder (GAD). Responses were analyzed with descriptive -statistics and compared using a χ or Mann-Whitney test.
Of the 518 completed surveys, 162 parents (31.3%) reported the administration of an unlicensed CBD product to a child with ADHD, ASD, and/or GAD. The highest prevalence of use was found in the West geographic region and among children diagnosed with GAD or with 2 or more diagnoses (i.e., ADHD, ASD, GAD). Parents who administered CBD products had more positive views of product safety and higher -perceived community support for usage.
Nearly one-third of parents have administered an unlicensed CBD product to a child with ADHD, ASD, and GAD. Health care providers should assess pediatric patients for CBD use and be prepared to engage parents in conversations regarding the safety of these products.
尽管无牌大麻二酚（CBD）产品的可得性不断增加，但评估其用于治疗儿童焦虑和神经发育障碍相关症状的数据有限。本研究的目的是量化被诊断患有焦虑和神经发育障碍的儿科患者中无牌CBD产品的使用情况，并比较给孩子使用CBD产品的父母与未使用的父母对CBD的看法。
在与儿科医疗保健专业人员进行预测试后，设计了一份包含31个条目的调查问卷。通过Qualtrics面板将完善后的调查问卷分发给美国7至18岁被诊断患有注意力缺陷多动障碍（ADHD）、自闭症谱系障碍（ASD）和/或广泛性焦虑障碍（GAD）的儿童的父母的代表性样本。使用描述性统计分析回答内容，并使用χ检验或曼-惠特尼检验进行比较。
在518份完成的调查问卷中，162名家长（31.3%）报告给患有ADHD、ASD和/或GAD的孩子使用了无牌CBD产品。使用 prevalence最高的是西部地区以及被诊断患有GAD或有两种或更多诊断（即ADHD、ASD、GAD）的儿童。使用CBD产品的父母对产品安全性的看法更积极，并且认为社区对使用的支持更高。
近三分之一的家长给患有ADHD、ASD和GAD的孩子使用了无牌CBD产品。医疗保健提供者应评估儿科患者是否使用CBD，并准备好与家长就这些产品的安全性进行沟通。
